# US 2022/0033507 A1 · Bispecific antibody targeting il-1r1 and nlpr3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033507 A1
- Document ID: US20220033507A1
- Status: Published application
- Kind: A1
- Application number: 17/275,986
- Filed: 2019-09-16
- Published: 2022-02-03
- Earliest claimed: 2018-09-14
- Assignees: University of Ulster
- Applicants: University of Ulster
- Inventors: Victoria McGILLIGAN
- Web page: https://patentgrep.com/patent/US20220033507A1

## CPC

- C07K 16/18: against material from animals or humans
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/77: Internalization into the cell
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure concerns modulators of the NLRP3 inflammasome pathway, in particular an NLRP3 inflammasome modulator which is capable of binding to both of IL-IR1 and NLRP3.

## Claims

### Claim 1

An NLRP3 inflammasome modulator that binds to one or more of IL-1 R1 and NLRP3.

### Claim 2 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator binds to the PYO domain of NLRP3.

### Claim 3 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator is selected from the group comprising: a polyclonal antibody, a monoclonal antibody, a humanized antibody, a chimeric antibody, a fusion protein, an aptamer molecule, a combination thereof, and fragments of each thereof.

### Claim 4 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator is a bi-antibody that binds to one or more of: IL-1R1 and NLRP3.

### Claim 5 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein modulator is a bi-antibody comprising one or more binding regions of a first antibody that binds to IL-1 R1 and one or more binding regions of a second antibody that binds to NLRP3.

### Claim 6 (depends on 5)

The NLRP3 inflammasome modulator of claim 5, wherein the bi-antibody comprises one or more complementary determining regions (CDRs) of a first antibody that binds to IL-1 R1 and one or more CDRs of a second antibody that binds to NLRP3.

### Claim 7 (depends on 5)

The NLRP3 inflammasome modulator of claim 5, wherein the first and/or second antibody is a monoclonal antibody.

### Claim 8 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator is an antibody fragment that binds to one or more of: IL-1 R1 and NLRP3.

### Claim 9 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator is a recombinant humanized antibody or antibody fragment that binds to one or more of: IL-1R1 and NLRP3.

### Claim 10 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator is an antibody or antibody fragment raised against one or more antigens of IL-1 R1 and NLRP3.

### Claim 11 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator is an antibody or antibody fragment raised against one or more antigens selected from one or more of NLRP3 and NLRP3 conjugated to Keyhole Limpet Haemocyanin (KLH) (NLRP3 immunogen); and one or more of IL-1 R1 and recombinant IL-1 R1.

### Claim 12 (depends on 10)

The NLRP3 inflammasome modulator of claim 10, wherein IL-1 R1 comprises an extracellular domain of IL-1 R1 (IL-1 R1 immunogen) comprising the sequence:
(SEQ ID NO: 1)
MKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPN
EHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVV
RNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEF
FKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTC
HASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQ
LICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLIT
VLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKLEGGPSV
FIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQT
QTHREDYNSTIRVVSHLPIQHQDWMSGKEFKCKVNNKDLPSPIERTISK
PKGLVRAPQVYTLPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHT
EENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYY
LKKTISRSPGK*.

### Claim 13 (depends on 11)

The NLRP3 inflammasome modulator of claim 11, wherein NLRP3 comprises one or more of KLH-EDYPPQKGCIPLPRGQTEKADHVD (SEQ ID NO: 30), KLH-linker-EDYPPQKGCIPLPRGQTEKADHVD (SEQ ID NO: 30), and KLH-Hydrazide-Ahx-EDYPPQKGCIPLPRGQTEKADHVD (SEQ ID NO: 30).

### Claim 14 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator is a bi-antibody comprising one or more binding regions of a first antibody raised against an extracellular domain of IL-1 R1 (IL-1R1 immunogen) and comprising the sequence:
(SEQ ID NO: 1)
MKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPN
EHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVV
RNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEF
FKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTC
HASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQ
LICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLIT
VLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKLEGGPSV
FIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQT
QTHREDYNSTIRVVSHLPIQHQDWMSGKEFKCKVNNKDLPSPIERTISK
PKGLVRAPQVYTLPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHT
EENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYY
LKKTISRSPGK*,
and one or more binding regions of a second antibody raised against NLRP3 conjugated to Keyhole Limpet Haemocyanin (KLH) (NLRP3 immunogen) comprising the sequence:
(SEQ ID NO: 30)
KLH-Hydrazide-Ahx-EDYPPQKGCIPLPRGQTEKADHVD.

### Claim 15 (depends on 1)

The NLRP3 inflammasome modulator of claim 1, wherein the modulator is a bi-antibody comprising one or more complementary determining regions (CDRs) of a first antibody raised against an extracellular domain of IL-1 R1 (IL-1 R1 immunogen) and comprising the sequence:
(SEQ ID NO: 1)
MKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPN
EHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVV
RNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEF
FKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTC
HASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQ
LICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLIT
VLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKLEGGPSV
FIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQT
QTHREDYNSTIRVVSHLPIQHQDWMSGKEFKCKVNNKDLPSPIERTISK
PKGLVRAPQVYTLPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHT
EENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYY
LKKTISRSPGK*,
and one or more CDRs of a second antibody raised against NLRP3 conjugated to Keyhole Limpet Haemocyanin (KLH) (NLRP3 immunogen) comprising the sequence:
(SEQ ID NO: 30)
KLH-Hydrazide-Ahx-EDYPPQKGCIPLPRGQTEKADHVD.

### Claim 16 (depends on 15)

The NLRP3 inflammasome modulator of claim 15, wherein the heavy chain CDRs of the first antibody comprise: GYPFTTAG (SEQ ID NO: 60); MNTQSEVP (SEQ ID NO: 61); and/or AKSVYFNWRYFDV (SEQ ID NO: 62); and/or wherein the light chain CDRs of the first antibody comprise: QSISDY (SEQ ID NO: 63); YAS; and/or QHGHSFPLT (SEQ ID NO: 64).

### Claim 17 (depends on 15)

The NLRP3 inflammasome modulator of claim 15, wherein the heavy chain CDRs of the second antibody comprise: GFTFSDYY (SEQ ID NO: 65); ISDGGTYT (SEQ ID NO: 66); and/or ARGWVSTMVKLLSSFPY (SEQ ID NO: 67); and/or wherein the light chain CDRs of the second antibody comprise: TGAVTTSNY (SEQ ID NO: 68); GTN; and/or ALWYSNYWV (SEQ ID NO: 69).

### Claim 18 (depends on 4)

The NLRP3 inflammasome modulator of claim 4, wherein the light chain of the bi-antibody has the amino acid sequence:
(SEQ ID NO: 57)
MVSSAQFLGLLLLCFQGTRCDIVMTQSPATLSVTPGDRVSLSCRASQSI
SDYLSWYQQRSHESPRLIIKYASQSISGIPSRFSGSGSGSDFTLSINSV
EPEDVGVYYCQHGHSFPLTFGSGTKLELKRADAAPTVSIFPPSSEQLTS
GGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMS
STLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC**.

### Claim 19 (depends on 4)

The NLRP3 inflammasome modulator of claim 4, wherein the heavy chain of a bi-antibody has the amino acid sequence:
(SEQ ID NO: 59)
MGWTLVFLFLLSVTAGVHSQIQLVQSGPELRKPGETVRISCKASGYPFT
TAGLQWVQKMSGKGLKWIGWMNTQSEVPKYAEEFKGRIAFSLETMSTAY
LQINNLKTEDTTYFCAKSVYFNWRYFDVWGAGTTVTVSSAKTTAPSVYP
LAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQS
DLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCP
PCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQ
ISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKV
NNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDF
MPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERN
SYSCSVVHEGLHNHHTTKSFSRTPGKGSAGGSGGDSEVQLVESGGGLVK
PGGSLKLSCAASGFTFSDYYMYWVRQTPEKRLEWVATISDGGTYTYYPD
SVKGRFTISRDNAKNNLYLQMNSLKSEDTAMYYCARGWVSTMVKLLSSF
PYWGQGTLVTVSAGGGGSGGGGSGGGGSQAVVTQESALTTSPGETVTLT
CRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIG
DKAALTITGAQTEDEAIYFCALWYSNYWVFGGGTKLTVLGQPK**.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A method for treatment and/or prophylaxis of an inflammation-related disorder, the method comprising:
administering a therapeutically effective amount of the NLRP3 inflammasome modulator of claim 1 that suppresses activation and/or signaling of the NLRP3 inflammasome to a subject in need of such treatment.

### Claim 22 (depends on 21)

The method of claim 21, wherein the NLRP3 inflammasome modulator is formulated as a medicament.

### Claim 23 (depends on 1)

A method to reduce or treat at least one symptom of an inflammation-related disorder in a subject comprising selectively inhibiting and/or reducing activation of the inflammasome pathway by administering to the subject an effective amount of the NLRP3 inflammasome modulator of claim 1.

### Claim 24

(canceled)

### Claim 25 (depends on 21)

The method of claim 21, wherein the inflammation-related disorder comprises one or more of: Atherosclerosis; inflammatory eye conditions such as Age-Related Macular degeneration, Dry Eye Syndrome, Glaucoma, Sjogren's syndrome; Diabetes; Inflammatory eye disease; Depression; Alzheimer's Disease; Parkinson's Disease; Inflammatory Bowel Disease; Rheumatoid Arthritis; Ageing; Dermatological conditions; and Cancer.
